Device Trial Radar · NCT07795606
An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
456,000
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Jan 31, 2027
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- BayerNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 31, 2026
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- Female only, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an observational study in which researchers will use claims data already collected from women in the United States who received their usual care. The study will look at women aged 40 years and older who have a uterus and started estrogen therapy. Estrogen therapy is often used to treat menopause symptoms, such as hot flashes and night sweats, or to help prevent bone loss. Women who take estrogen and still have a uterus usually also need a progestogen to help protect the lining of the uterus. Without this protection, the lining may become too thick. This can lead to endometrial hyperplasia and may increase the risk of endometrial cancer. This study will look at how Mirena and other progestogen treatments are used in routine medical care to protect the lining of the uterus during estrogen therapy. Mirena is a small device placed in the uterus that releases the hormone levonorgestrel (a synthetic progestogen, similar to progesterone). In the United States, Mirena is approved for birth control and for treatment of heavy menstrual bleeding. Clinicians may also use it for endometrial protection during estrogen therapy. Bayer's Mirena levonorgestrel-containing intrauterine system (LNG-IUS) 52 mg is approved for endometrial protection during hormone therapy in over 100 countries outside of the US. The main purpose of this study is gain insight into how different progestogen treatments are used in the context of estrogen therapy in women with a uterus, and the health outcomes linked with them. Researchers will describe how often women use estrogen alone, estrogen with Mirena, or estrogen with other progestogen treatments in the past 10 years. Researchers will also look at how often endometrial hyperplasia, endometrial cancer, abnormal or heavy bleeding, and hysterectomy occur in these groups over time. The data will come from two U.S. health insurance claims databases: Optum Clinformatics Data Mart and MarketScan Commercial Claims and Encounters Database. The study period covers 2014 through 2025, depending on the database. Optum: January 2015-December 2025 and MarketScan: October 2014-September 2025, with patient identification periods of Optum: January 2016-December 2024 and MarketScan: October 2015-September 2024. Researchers will follow each participant's available data for at least 12 months before and at least 12 months after starting estrogen therapy, with follow-up of up to 10 years. No study treatment will be given as part of this study. Researchers will only review anonymous health insurance claims data that were already collected during routine care.
Conditions
- Estrogen Therapy
Interventions
Estrogen therapyDrug
Estrogen therapy prescribed during routine clinical practice and identified through prescription claims data. Exposure to estrogen therapy is determined using study-specific claims-based definitions.
Mirena levonorgestrel-releasing intrauterine systemDevice
A levonorgestrel-releasing intrauterine system used for endometrial protection in women receiving estrogen therapy. Exposure is identified through Mirena insertion procedure codes and/or device codes in claims data. Contraception use of this product is not exposure of interest and baseline hormonal contraception is an exclusion criterion.
Other progestogen therapyDrug
rogestogen therapy used for endometrial protection in women receiving estrogen therapy, including progesterone, synthetic progestins, Liletta LNG-IUS 52 mg, and combination estrogen-progestogen products. Exposure is identified through claims data. Contraceptive use of these products is not exposure of interest, and baseline hormonal contraception is an exclusion criterion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients receiving estrogen therapyTime frame: Retrospective analysis from January 2025 to December 2025
- Number of patients by treatment subgroup within 30 and 90 days of estrogen therapy initiationTime frame: Within 30 days and 90 days after estrogen therapy initiation during the study period (January 2025 to December 2025)
- Proportion of patients by treatment subgroup within 30 and 90 days of estrogen therapy initiationTime frame: Within 30 days and 90 days after estrogen therapy initiation during the study period (January 2025 to December 2025)
1 more outcomes with a free account
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Mirative MarketScan Commercial Claims and Encounters Database
Ann Arbor, Michigan
Optum Clinformatics™ Data Mart (CDM)
Eden Prairie, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.